Alltracel Successfully Develops Novel Nano-Fibre Delivery Platform for its Patented m.doc(TM) Woundcare Technology

DUBLIN, Ireland and PRAGUE, Czech Republic, March 16

Mar 16, 2006, 00:00 ET from Alltracel Pharmaceuticals Plc.

/PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., ("Alltracel", or
 "the Company"), (AIM: AP.L), the Medical Technology Company focussed on the
 Woundcare, Oralcare and Cardiovascular Health markets today announces the
 successful development of an effective nano-fibre based delivery platform for
 its patented m.doc(TM) based woundcare technology.
     This month's final haemostasis efficacy studies on m.doc(TM) based
 nano-fibre woundcare prototypes have proven both effective and efficient
 haemostasis. This follows nine months of technical evaluation and prototype
 testing with Alltracel's nanotechnology development partner ELMARCO s.r.o.
 ("Elmarco") of the Czech Republic.
     Manufacturing discussions are now taking place with existing and new
 manufacturing partners to incorporate this technology into existing and new
 woundcare delivery systems for both the consumer and professional markets.
     Elmarco ( is a specialist R&D and manufacturing company
 that has developed, in conjunction with the Technical University of Liberic,
 a novel proprietary & patented process for spinning polymers into nano-scale
 fibres for a range of industrial, chemical, micro-electronic and bio-medical
     Alltracel's CEO, Tony Richardson, commented: "Alltracel has always been
 committed to innovation and the development of our proprietary m.doc(TM)
 technology. We are extremely pleased to have worked closely with our
 development partner Elmarco in undertaking this research which has resulted
 in a breakthrough in the advancement of nano-fibre delivery systems.
     This novel nano-fibre based m.doc(TM) delivery platform enables not only
 the development of new m.doc(TM) products and delivery systems but also the
 cost effective re-engineering of existing m.doc(TM) delivery systems.
     We are now focussed on manufacturing partnership discussions for both
 consumer and professional woundcare products and are targeting to have the
 first m.doc(TM) based nano-fibre products on the market this year."
     Notes to Editors:
     Alltracel (AIM: AP.L) ( Alltracel Pharmaceuticals Plc
 is a Medical Technology Company focussed on the Woundcare, Oralcare and
 Cardiovascular Health markets.
     With corporate headquarters in Dublin, Ireland; Alltracel has a
 commercial office in London, England; R&D subsidiary in the Czech Republic
 and manufacturing facilities in Shenzhen, China. Alltracel was founded in
 1996 and listed on London's Alternative Investment Market in July 2001.
     Alltracel's has a number of patents in the areas of polysaccharide
 manipulation and PTFE processes and products as well as a significant
 collaborative R&D programme in place focussed on its markets.
     In the Woundcare market m.doc(TM) (Micro Dispersed Oxidized Cellulose;
 ( is the trading name given to Alltracel's patented technology
 which is proven as an effective and efficient haemostatic (blood-stopping)
     - In the consumer Woundcare sector m.doc(TM) is currently being marketed
 as the leading stops bleeding ingredient brand within recognized woundcare,
 and relevant first-aid brands worldwide.
     - Alltracel's woundcare technology is also currently poised for entry
 into the professional Woundcare and specialist Oralcare markets.
     Within the Cardiovascular Health market Alltracel (
 has developed a novel bioactive compound that, following two years of
 scientific research including in vitro, pre-clinical and clinical trials,
 indicates cardiovascular health (CVH) benefits on its own and in combination
 with existing CVH products.
     Alltracel's patented process utilises a derivative of cellulose fibre to
 produce a bioactive with scientifically proven properties that aid CVH;
 specifically lowering LDL cholesterol, reducing blood glucose levels and
 helping to prevent arterial plaque build up.
     The end result is a pioneering, value-adding bioactive that can enhance
 and differentiate current cardiovascular health products and that can add
 benefit to current non-health benefiting nutritious finished foods.
     - Further efficacy, dosage, timing/phasing and combination (with other
 bio-actives) studies to determine optimum delivery systems, formats and
 combinations in both the functional foods and pharmaceutical markets are
     - Development discussions with potential partners in the functional foods
 and pharmaceutical sectors in the EU, Asia and North America have commenced.
     m.doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.
     For Further Information Contact:
     Dublin: Kathy Wray
     Alltracel: +353-1-235-2162,
     London: Sarah MacLeod
     Financial Dynamics:
     New York: Sean Leous
     Financial Dynamics:

SOURCE Alltracel Pharmaceuticals Plc.